Compare Mesoblast Limited (MESO) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Mega Cap Growth ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Vanguard Mega Cap Growth ETF trades at $87.67. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | MGK | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.96 | $92.06 |
52-Week Low | $12.88 | $70.70 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.83 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its low expense ratio of 0.05% and concentrated portfolio of 69 large-cap growth stocks, including heavy exposure to technology leaders. A 1:5 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 2026.
MGK offers exposure to top U.S. growth companies but faces risks from high concentration in tech stocks and market volatility. Its long-term performance history and cost efficiency present opportunities for growth-focused investors, though sector-specific downturns could impact returns significantly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
